Japan-based Chugai Pharmaceutical has revealed plans to expand its research subsidiary in Singapore, Chugai Pharmabody Research (CPR), in order to enhance its drug discovery capabilities.

As part of the expansion, the company is extending the operations of the subsidiary for additional five years from 2022 to 2026, with SGD282m ($207.03m) investment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CPR was founded in 2012 to carry out research for the discovery of new antibody drugs using Chugai’s antibody engineering technologies.

Originally, the operation period was planned to be five years until 2016, but an initial investment of SGD476m ($349.46m) was announced for ten years from 2012 to 2021.

Chugai Pharmaceutical Research and Translational Clinical Research executive vice-president Hisafumi Okabe said: “Chugai Group’s drug discovery approach has successfully generated new breakthrough drugs including Actemra and Hemlibra by utilising our proprietary advantage including antibody engineering technologies.

“We seek to accelerate creation of drug candidates with the next-generation antibody technologies by combining expertise of our three research laboratories, CPR, Kamakura Research Laboratories, and Fuji Gotemba Research Laboratories, toward continuous creation of innovation in the future.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We seek to accelerate creation of drug candidates with the next-generation antibody technologies.”

The company is also planning to build a new synthetic research facility at its Ukima Research Laboratories in Tokyo, Japan, to advance the process development of small and medium-sized molecule active pharmaceutical ingredients (APIs).

Chugai will equip the new building with research facilities for high-potency APIs (HPAPIs). The facility will feature advanced containment technologies to ensure safety by preventing leakage and exposure to chemical compounds.

Additionally, the company will install new equipment and instruments in order to increase research efficiency and adopt a layout that expedites communication among researchers.

The improved innovation and research productivity are aimed at accelerating the process development for new therapeutic candidates.